Background Accumulating evidence suggests a beneficial effective of tumour necrosis factor‐
alpha (TNF‐α) inhibitors on the outcomes of COVID‐19 disease, which, however is not …

The COVID-19 pandemic has raised considerable concerns that patients with inflammatory
bowel disease (IBD), particularly those treated with immunosuppressive therapies, may …

Objectives We aimed to determine whether changes in acute severe colitis (ASC)
management have translated to improved outcomes and to develop a simple model …

Abstract Background and Aims Age is a major prognostic factor for COVID-19 outcomes. The
effect of inflammatory bowel disease [IBD] activity on COVID-19 is unclear. We examined the …

Acute severe ulcerative colitis (ASUC) is a distinctive ulcerative colitis flare presentation
characterised by the presence of systemic inflammation as well as bloody diarrhoea, and …

Background Despite rescue therapy, acute severe ulcerative colitis (ASUC) is associated
with a high risk of colectomy, while treatment options remain limited. Tofacitinib, a rapidly …

Abstract The coronavirus disease 2019 (COVID-19) pandemic has been associated with
significant morbidity and mortality. Following the introduction of vaccines, various side …

Abstract Background and Aims The coronavirus disease 2019 (COVID‐19) pandemic has
affected the management of inflammatory bowel disease (IBD) patients. Elective operations …

Abstract The coronavirus disease 2019 (COVID-19) pandemic has led to unprecedented
disruptions in fellowship training programs worldwide. In gastroenterology, the strain in …

Introduction Acute severe ulcerative colitis (ASUC) is a critical manifestation of ulcerative
colitis (UC), often necessitating colectomy when medical management fails. Despite …